EE583 Cost-Effectiveness of Dapagliflozin in the Treatment of Chronic Symptomatic Heart Failure With Reduced Ejection Fraction in the Netherlands
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.823
https://www.valueinhealthjournal.com/article/S1098-3015(22)03027-3/fulltext
Section Title :
Section Order :
10368
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03027-3&doi=10.1016/j.jval.2022.09.823